Worm.com

Guide to Spyware and AntiVirus Information

You are currently browsing the Worm.com weblog archives for the day Thursday, June 19th, 2008.

 

Sponsors

Archive for June 19th, 2008

Fortinet® — the pioneer and leading provider
of unified threat management (UTM) solutions — today announced that the
United States Patent and Trademark Office has awarded the company four
additional patents for network virtualization and security related
inventions. These new patents strengthen Fortinet’s growing intellectual
property portfolio, bringing Fortinet’s total awarded patents to 17.

The four new patents reflect Fortinet’s focus, as a leading UTM vendor, on
innovative methods for efficiently processing network data while applying
various security-related filtration processes within a consolidated and
accelerated platform. Three of the newly awarded patents are directed to
the routing and processing of data in virtualized environments. In addition
to these four new patents, Fortinet has more than 80 patent-pending and
in-process applications.

“These patents support Fortinet’s innovation and vision for an integrated,
multi-threat and virtualized approach to network security — groundswell
areas for the networking and security industries,” said Michael Xie, CTO
and co-founder of Fortinet. “As we continue our strong research and
development efforts, our growing patent portfolio provides momentum for
accelerating the course of innovation we are undertaking.”

Fortinet’s new patents are key in propelling some of the highest impact
technologies and business trends of the day — security consolidation and
virtualization. As enterprise companies of all sizes look for ways to
economize without compromising the safety of their networks, security
consolidation and virtualization provide a powerful approach for maximizing
both human and capital resources.

Integrated network and application security, together with virtualization
technologies, offer a powerful and synergistic approach for defending
against an increasingly dangerous cyber-criminal environment. In
combination with its extensive patent-pending applications and patents
already granted, Fortinet’s newest patents address critical technologies
that enable comprehensive network protection:

--  U.S. Patent #7,333,430 - Systems and Methods for Passing Network
    Traffic Data - directed to efficiently processing network traffic data to
    facilitate policy enforcement, including content scanning,
    source/destination verification, virus scanning, content detection and
    intrusion detection;
--  U.S. Patent #7,340,535 - System and Method for Controlling Routing in
    a Virtual Router System - directed to controlling the routing of network
    data, and providing efficient configuration of routing functionality and
    optimized use of available resources by applying functions to data packets
    in a virtual environment;
--  U.S. Patent #7,376,125 - Service Processing Switch - directed to
    providing IP services and IP packet processing in a virtual router-based
    system using IP flow caches, virtual routing engines, virtual services
    engines and advanced security engines;
--  U.S. Patent # 7,389,358 - Distributed Virtual System to Support
    Managed, Network-based Services - directed to a virtual routing system,
    which includes processing elements to manage and optimize IP traffic,
    useful for service provider switching functions at Internet point-of-
    presence (POP) locations.
    

About Fortinet ( www.fortinet.com )

Fortinet is the pioneer and leading provider of ASIC-accelerated unified
threat management, or UTM, security systems, which are used by enterprises
and service providers to increase their security while reducing total
operating costs. Fortinet solutions were built from the ground up to
integrate multiple levels of security protection — including firewall,
antivirus, intrusion prevention, VPN, spyware prevention and anti-spam –
designed to help customers protect against network and content level
threats. Leveraging a custom ASIC and unified interface, Fortinet solutions
offer advanced security functionality that scales from remote office to
chassis-based solutions with integrated management and reporting. Fortinet
solutions have won multiple awards around the world and are the only
security products that are certified in seven programs by ICSA Labs
(firewall, antivirus, IPSec, SSL, network IPS, anti-spyware and anti-spam).
Fortinet is privately held and based in Sunnyvale, California.

Copyright © 2008 Fortinet, Inc. All rights reserved. Fortinet is a
registered trademark of Fortinet, Inc. FortiGate, FortiOS, FortiAnalyzer,
FortiASIC, FortiCare, FortiManager, FortiWiFi, FortiGuard, FortiClient,
FortiReporter and other names are trademarks of Fortinet, Inc. in the
United States and/or other countries. All other trademarks referred to
herein are the property of their respective owners.

Media Contact:
Kim Nguyen
Fortinet, Inc.
(408) 486-5458
knguyen@fortinet.com

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

BOSTON, and CHIPIONA (Cadiz), Spain, June 19 /PRNewswire/ — Carbonite, Inc. today announced the release of the Spanish version of Carbonite Online Backup and the appointment of Draque Multimedia SL as its publisher in Spain.

Carbonite Online Backup is the leading consumer backup service in the United States and Canada. The fully-localized Spanish version is now available for purchase in Spain from Draque at 49.95 euros (including VAT) for a one-year subscription and at 89.98 euros for a two-year subscription. An unlimited 15-day free trial of the Spanish version, with no credit card required, is also available at http://www.draque-carbonite.com/ .

Carbonite installs with just a few clicks and runs quietly in the background, continually backing up all data files. It is completely automatic - once installed, Carbonite finds all new and changed files and continues to back them up whenever the PC is connected to the Internet. Storage capacity is unlimited - users never outgrow their Carbonite subscription no matter how much data they have. Carbonite never interferes with the speed of the user’s PC or Internet browsing. Data is encrypted before leaving the local computer and is transmitted to Carbonite’s secure data center using HTTPS (SSL) for total privacy.

"Last summer, we released the German and French versions of Carbonite Online Backup. Now, we are delighted to be adding Spain to our distribution network in Europe by partnering with Draque," said Floyd Bradley, Carbonite’s EVP International. "We look forward to working with Draque to increase Carbonite’s market presence on the continent."

Francisco Diaque, Director General of Draque, added, "Carbonite’s online backup solution is the best option for consumers, small office/home office (SOHO) customers and small and medium-sized businesses (SMBs) because of its great features: it is easy to use and control, it contains high security rules to keep data safe and it has the best price in the market for an unlimited backup solution."

About Carbonite

Carbonite launched its Online PCBackup(TM) service in May 2006. Carbonite’s industry-first offer of unlimited backup space for a flat low price revolutionized the market for consumer and small business backup services. So far the company has backed up over 3 billion files, has restored more than 200 million lost files for its customers and has a large data center where capacity is measured in petabytes. There are Carbonite users in over 115 countries.

Founded in 2005, Carbonite believes that computer users should not have to think about backup. The company’s mission is to provide an affordable, reliable, secure and easy-to-use solution for the mainstream computer user. Carbonite is available to consumers and small business through numerous channels, including its corporate website, major US retailers and international distributors. For more information, please visit http://www.carbonite.com/ .

About Draque

Draque Multimedia was founded in 1996 and is based in Chipiona (near Cadiz), Spain. The company is the leader in distribution in Spain for entertainment PC software, accessories, consoles and photography. Draque is the exclusive distributor of the Nero product line, and also represents SOFTWIN’s BitDefender antivirus product line in Spain. For more information, please visit http://www.draque.com/

CONTACT: Tim Wieland of Airfoil Public Relations for Carbonite, Inc., +1-248-304-1414

Web site: http://www.carbonite.com/ http://www.draque.com/ http://www.draque-carbonite.com/

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

QED Connect, Inc., (PINKSHEETS: QEDC), an
innovative Software-as-a-Service (SaaS) provider for the information
security market, today announced the addition of the Empire Hotel Group, a
distinctive collection of five New York hotels, to its customer base. The
Empire Hotel Group implemented QED’s flagship software, Omni Manager, to
help meet its business objectives of increasing employee productivity at
its reservation and front desk operations centers. Omni Manager is a
powerful tool for monitoring, managing and reporting on employee Internet
use, and also provides added security by blocking access to web sites that
could introduce viruses or malware onto the network. The Empire Hotel Group
currently has Omni Manager running at three of its five Manhattan
properties, including the Empire Luxury Collection’s Lucerne Hotel and
Belvedere Hotel, and the Empire Collection’s Travel Inn Hotel.

“We have different reservation centers in each hotel and found that some of
our reservationists were using the Internet for non-work related purposes,
which detracted from overall room sales,” said Glenn Isaacs, Vice
President, Empire Hotel Group. “Omni Manager enabled us to block access to
certain Internet sites in shopping, social networking and other categories
that were taking up prime productive time. Omni Manager is directly
responsible for a 7% increase in the volume of reservations and resulting
revenue we’ve seen. Employees can now concentrate on critical job functions
instead of being distracted by the Internet.”

Continues Isaacs, “We also looked into buying traditional software
solutions that would be manually installed on our computers, but realized
that a hosted solution like Omni Manager would be easier and more
cost-effective to administer and manage. The monthly subscription model is
efficient for us, and we never have to worry about software upgrades or
patches — it all happens automatically.”

About QED Connect, Inc.

QED Connect, Inc. is an information security Software-as-a-Service (SaaS)
provider that gives organizations visibility, management and control of
activity on all their computers, laptops and wireless devices. The
company’s popular SaaS, Omni Manager, is an affordable way to monitor and
manage how employees are using company computers and the Internet at any
time, from any location in the world. This solves the problems created by
today’s ‘virtual’ work environment of branch offices, remote workers and
traveling employees. Omni Manager is a web-hosted software application that
includes e-mail and Internet filtering and blocking, antivirus, instant
messaging management, asset tracking, application usage monitoring and
policy management. ROI is delivered by employee productivity gains, cost
savings and improved operational efficiencies. For more information, visit
www.qedconnect.com .

Safe Harbor Statement

Certain statements in this press release that are not historical facts are
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements may be identified by the use
of words such as “anticipate,” “believe,” “expect,” “future,” “may,”
“will,” “would,” “should,” “plan,” “projected,” “intend,” and similar
expressions. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual results,
performance or achievements of QED Connect, Inc., (the Company) to be
materially different from those expressed or implied by such
forward-looking statements. The Company’s future operating results are
dependent upon many factors, including but not limited to the Company’s
ability to: (i) obtain sufficient capital or a strategic business
arrangement to fund its expansion plans; (ii) build the management and
human resources and infrastructure necessary to support the growth of its
business; (iii) competitive factors and developments beyond the Company’s
control; and (iv) other risk factors.

For investor inquiries:
Email Contact

For media inquiries:
Email Contact

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Hepatitis C Virus Market is One of the Most Active Areas of Infectious Disease Drug Development in Recent Years, According to a New Report from Decision Resources

WALTHAM, Mass., June 19 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that market to treat hepatitis C virus will grow by nearly five-fold during the next decade, increasing from approximately $2 billion in 2007 to more than $10 billion in 2017 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The new Pharmacor report entitled Hepatitis C Virus finds that, as drug makers have recognized the high unmet need and significant commercial potential that exists, the hepatitis C virus market has been one of the most active areas of infectious disease drug development in recent years.

According to the report, market growth over the next decade will be driven by the introduction of novel agents in the protease inhibitors and polymerase inhibitors drug classes that specifically target the hepatitis C virus. Among the range of products in clinical development, the most promising agents in these classes include Vertex/Johnson & Johnson/Mitsubishi Tanabe’s telaprevir, Schering-Plough’s boceprevir, Roche’s R-1626, Roche/Pharmasset’s R-7128, Roche/InterMune’s ITMN-191, Tibotec’s (Johnson & Johnson) TMC-435350, and Pfizer’s PF-868554. Currently available clinical data suggests that all of these orally administered agents have the potential to significantly improve the efficacy of treatment, achieving higher sustained virologic response than current treatment, particularly in difficult-to-treat genotype 1 patients.

The hepatitis C virus market has been dominated by Roche and Schering-Plough, and both companies market pegylated interferon-alpha and ribavirin agents. These two companies have competed intensely in this market and have attempted to differentiate their pegylated interferon products, with Roche gaining an edge in market share. Through internal development and collaboration, Roche and Schering-Plough have developed next generation products that will allow them to remain key players in the hepatitis C virus market through 2017.

"Hepatitis C virus, which represents a large and relatively under-tapped market, has a complex epidemiology and is characterized by a large and aging chronically infected patient population which, over the next decade, is projected to increasingly present with late-stage complications of the infection, such as cirrhosis," said John Lebbos, M.D., director at Decision Resources. "Since current treatment with pegylated interferon-alpha agents and ribavirin achieves cure in less than half of patients and is associated with significant side effects, substantial opportunity exists for drug developers that can deliver safer and more effective therapies."

About Decision Resources

Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:
  Elizabeth Marshall
  Decision Resources, Inc.
  781-296-2563
  emarshall@dresources.com

CONTACT: Elizabeth Marshall, Decision Resources, Inc., +1-781-296-2563, emarshall@dresources.com

Web site: http://www.decisionresources.com/

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Drugs that suppress HIV are keeping infected individuals alive and relatively healthy for years, even decades. But studies suggest that a new health risk is emerging for these long-term survivors: increased odds for heart attack and stroke.

It’s not clear whether the cause is the virus itself or the drugs used to treat it, said Dr. Steven Grinspoon, professor of medicine at Harvard University.

The exact cause of heightened heart risk among HIV patients “may not be just one or the other,” he said. “Both may act, in different ways. The drugs may be causing metabolic problems such as dyslipidemia in the traditional way, while the virus can cause inflammation, which is a known factor in atherosclerosis.”

Dyslipidemia is an abnormal increase in levels of blood fats such as cholesterol. Having HIV is associated with low levels of “good” HDL cholesterol and high levels of the blood fats …


Read the full article with a Free Trial at MyWire.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Trinity Biotech plc (NASDAQ: TRIB), a
leading developer and manufacturer of diagnostic products for the
point-of-care and clinical laboratory markets, today announced that it will
preside over the closing of The NASDAQ Stock Market in recognition of U.S.
National HIV Testing Day.

June 27, 2008, marks the fourteenth annual U.S. National HIV Testing Day,
an annual campaign sponsored by the National Association of People with
AIDS to encourage at-risk individuals to receive voluntary HIV counseling
and testing. According to the Centers for Disease Control and Prevention,
an estimated 180,000 to 280,000 Americans are HIV-positive but are unaware
of their status. HIV counseling and testing enables people with HIV to take
steps to protect their own health and that of their partners, and helps
people who test negative to get the information they need to stay
uninfected.

Dr. Monica Sweeney, Assistant Commissioner of the New York City Health
Department’s Bureau of HIV/AIDS Prevention and Control, was quoted as
saying, “National HIV Testing Day reminds us of the importance of knowing
your HIV status. Let’s work to make testing a routine part of medical
care, which is the best way to save lives.”

Brendan Farrell, Chief Executive Officer of Trinity Biotech, commented, “We
are honored to assist so many dedicated health jurisdictions to help stem
the spread of the HIV virus, and proud to be able to close The NASDAQ Stock
Market on such an important date. In order to help stop the spread of
HIV/AIDS and provide treatment to those in need, it is critical that
individuals who may be infected learn their HIV status. We believe that
Trinity’s Uni-Gold(TM) Recombigen® HIV test, with its 10 minute result,
earlier detection capability, and 100% sensitivity, will increase the
number of people who learn their HIV results, and we will continue to work
aggressively in partnership with local, state and national agencies to help
make this happen.”

Trinity’s Uni-Gold(TM) Recombigen® HIV test was launched in the USA in
2004. Since then sales of the product have grown rapidly through increased
penetration of both the public health and hospital based markets. In a
recent study, Uni-Gold™ demonstrated far superior performance to all
currently available FDA approved CLIA-waived rapid tests currently
available on the market. Furthermore, this highly accurate test, with 100%
sensitivity, even outperformed an FDA-approved, “moderately complex” rapid
test. For further information on rapid HIV testing and Uni-Gold(TM)
Recombigen® HIV, please see: http://www.unigoldhiv.com/ or call
800.325.3424.

On June 27, 2008, NASDAQ will host New York City Department of Health
Assistant Commissioner Dr. Monica Sweeney, M.D. together with Brendan
Farrell, Trinity’s Chief Executive Officer, and David Oxley, Trinity’s
Executive Vice President, to preside over the NASDAQ Market Close ceremony,
beginning at 3:50 p.m. ET. Following the event, the Market Close ceremony
will be available for viewing online at
http://www.nasdaq.com/reference/marketsite_about.stm .

Trinity Biotech develops, acquires, manufactures and markets diagnostic
systems, including both reagents and instrumentation, for the point-of-care
and clinical laboratory segments of the diagnostic market. The products are
used to detect infectious diseases and blood coagulation disorders, and to
quantify the level of Haemoglobin A1c and other chemistry parameters in
serum, plasma and whole blood. Trinity Biotech sells direct in the United
States, Germany, France and the U.K. and through a network of international
distributors and strategic partners in over 75 countries worldwide. For
further information please see the Company’s website:
www.trinitybiotech.com .

Forward-looking statements in this release are made pursuant to the “safe
harbor” provision of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks
and uncertainties including, but not limited to, the results of research
and development efforts, the effect of regulation by the United States Food
and Drug Administration and other agencies, the impact of competitive
products, product development commercialization and technological
difficulties, and other risks detailed in the Company’s periodic reports
filed with the Securities and Exchange Commission.

Contact:
Trinity Biotech plc
Ms. Niamh Long
Investor Relations Officer
(353)-1-2769800
Email Contact

Joe Diaz, Joe Dorame, Robert Blum
Lytham Partners, LLC
(602) 889-9700

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

ATLANTA, June 19 /PRNewswire-FirstCall/ — EAU Technologies, a leading provider of Electrolyzed Water — EMPOWERED WATER(TM) — for high-volume, business-to-business applications, today announced that an analyst’s report dated June 10, 2008 has been issued by Catalyst Financial Resources. Catalyst Financial Resources assists small-cap companies in gaining recognition in the financial marketplace.

EAU Technologies manufactures Empowered Water(TM) generators that employ electrolysis to produce high volumes of electrolyzed oxidative and reductive water for business-to-business applications. The generators use a unique combination of cell technology, salt and electricity to alter the molecular structure of water to create a non-toxic oxidized antimicrobial solution capable of killing many pathogens in less than a minute, while also creating an alkaline solution capable of replacing caustic cleaners and soaps without toxicity.

About EAU:

EAU Technologies, Inc. (EAU) is a supplier of Electrolyzed Water Technology (EW Technology marketed as Empowered Water(TM)) and other complementary technologies with applications in diverse industries. EAU’s water-based and non-toxic solutions (at application concentration, the solutions are non-toxic to humans and live animals) may replace many of the traditional methods now used to clean, disinfect and nourish in large industries such as agriculture and food processing. EAU has solutions for existing bacteria, virus and mold proliferation threats. EAU continues to add innovative and efficacious products that offer a systemic approach to pathogen elimination in food processing plants and related industries, thereby producing safer foods while protecting the environment through "Green Technology." EAU has developed patent pending systems that are being used on dairies to process drinking water for dairy herds. Studies and trials are showing promising results at improving animal digestion which shows signs of improved animal health and production. EAU uses terms like "green", "natural", "non-toxic" and "organic" based on our NAMSA studies that show no toxicity or cytotoxicity at levels as high as 70 ppm of HOCl. EAU uses only water, food grade electrolytes and electricity to create all of its solutions. The active ingredients in the solutions EAU creates through electrolysis are GRAS (generally regarded as safe) approved. Please visit our website and sign up to be emailed our press releases and public announcements. http://www.eau-x.com/

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements may include without limitation, our expectations about the growth and the potential for the company, and Mr. Bradley’s abilities to lead the company in that growth. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk associated with successfully developing our business in evolving markets, our need for additional capital, our continuing operating losses, the ability of our management to conduct distribution activities and sell products, possible failure to successfully develop new products, vulnerability to competitors due to lack of patents on our products, and other risk factors listed in our annual report on Form 10-KSB for the year ended December 31, 2007 and our other SEC reports. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.

CONTACT: Joe Stapley, EAU Technologies, +1-678-384-3716, or Sharon Kraun, Cohn, Overstreet & Parrish, +1-404-961-2242

Web site: http://www.eau-x.com/

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy: